| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 80 | 170 | 110 | 110 | 130 |
| Sales Growth | -52.94% | +54.55% | unch | -15.38% | -18.75% |
| Net Income | -7,620 | -5,420 | -4,840 | -1,950 | -2,000 |
| Net Income Growth | -40.59% | -11.98% | -148.21% | +2.50% | +16.32% |
Mangoceuticals Inc (MGRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Mangoceuticals Inc. is involved in developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction drug branded `Mango`. Mangoceuticals Inc. is based in DALLAS, TX.
Fiscal Year End Date: 12/31